0QNO.L
LONZA GROUP AG LONZA GROUP ORD
£496.72
-0.72%
2026-06-01
About LONZA GROUP AG LONZA GROUP ORD
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Key Fundamentals
P/E Ratio
0.13
EPS (TTM)
£39.52
ROE
10.5%
Profit Margin
-4.2%
Debt/Equity
58.74
Price/Book
4.42
Beta
0.82
Market Cap
£35.66B
Avg Volume (10D)
76K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
£544.00
60D Low
£455.10
Avg Volume
99K
Latest Close
£496.72
Get breakout alerts for 0QNO.L
Sign up for Breakout Scanner to receive daily notifications when 0QNO.L triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
LONZA GROUP AG LONZA GROUP ORD (0QNO.L) is listed on the London Stock Exchange (LSE). Breakout Scanner monitors 0QNO.L daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups.. Data is provided for informational purposes only and does not constitute financial advice.